超碰97人人爱人人做-超碰97人人操-超碰97人人操人人干-超碰97人人操人人摸-超碰97人人艹-超碰97人人干人人爱

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 欧美性一区二区三区 | 欧美精品1区国新欲乱视频 国产精品一区二区无线 | 日本阿v视频高清在线中文 银杏影视 | 日本xx | 给我免费播放片国语电影 | 久这里只有精品国产66热99 | 精品国产第 | 中文在线日韩亚洲欧美 | 91色在线| 国产亚洲老 | 欧美mv | 国产精品国产一级按摩a√ 日韩精品专区在线影 | 二区三区爱欲九九 | 欧美日韩国产高清视频在线观看 | 国产午夜福利在线 | 97碰碰碰视频在线观看 | 国产又色又爽又刺激在线观 | 日韩精品一区二区三区在线视频放 | 国产精品福利电影一区二区三 | 国产亚洲男人的天堂在线观看 | 国产美女一级做a视频免费 国语自产免费精品视频一区二区 | 女性女同性aⅴ免费观看 | 免费动漫网站 | 国产www在线播放 | 国产偷国产偷亚洲高清日韩 | 日韩欧美国产综合在线播放 | 欧美国产日本韩在线 | 欧美在线伊人 | 国产又黄又刺 | 国偷自产中文二区三区蜜桃传媒 | 国产二区精品视频 | 国产午夜福利免费看片 | 56prom精品视频在放免费 | 日韩在线观看一区二区三区 | 亚洲一区二区三区精品动漫 | 又湿又紧又大又爽a视频国产 | 熟女视频一区二区在线观看 | 国产精品边做奶水狂喷 | 欧亚精品卡一卡二卡三 | 日韩一级在线播放 | 在线丝瓜 |